

## Sponsored Symposium

**BONE QUALITY IS A MAJOR DETERMINANT OF  
ANTIFRACTURE EFFICACY OF BONE ACTIVE AGENTS IN  
POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS**

Chairpersons: **Adami S.** (Verona, Italy)  
**Agnusdei D.** (Florence, Italy)

hour:		abstract bk. page ref.:
14.00	BONE QUALITY: FROM BENCH TO BEDSIDE <b>Bouxsein M.L.</b> (Boston, MA, USA)	9
14.30	CLINICAL USE OF RALOXIFENE IN POSTMENOPAUSAL WOMEN <b>Delmas P.D.</b> (Lyon, France)	9
15.00	RALOXIFENE: SHORT AND LONG-TERM CHOICE FOR OSTEOPOROSIS PREVENTION AND TREATMENT <b>Brandi M.L.</b> (Florence, Italy)	9
15.30	<i>End of the Session</i>	
15.30 - 16.00	<i>Break</i>	